within Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B02A_Antifibrinolytics.B02AA01_AminocaproicAcid;

model AminocaproicAcid_1
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.9,
    Cl = 2.4999999999999998e-06,
    adminDuration = 600,
    adminMass = 5000 / 1000000,
    adminCount = 1,
    Vd = 0.00026000000000000003,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0013333333333333333,
    Tlag = 1020);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>AminocaproicAcid_1</td></tr><tr><td>ATC code:</td><td>B02AA01_1</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>5000</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.26</td><td>L</td></tr>
    <tr><td>clearance:</td><td>150</td><td>mL/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Aminocaproic acid is a synthetic derivative of the amino acid lysine and acts as an antifibrinolytic agent by inhibiting plasminogen activation, thereby reducing fibrinolysis and bleeding. It is primarily used to control excessive bleeding in conditions such as fibrinolytic states (e.g., after surgery, trauma, or bleeding disorders). Aminocaproic acid is approved and in clinical use in several countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy volunteers after oral administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.B.B02AA01_1 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end AminocaproicAcid_1;
